Etodolac, a cyclooxygenase-2 inhibitor, attenuates paclitaxel-induced peripheral neuropathy in a mouse model of mechanical allodynia.

The Journal of pharmacology and experimental therapeutics 20120701

Self-organizing molecular field analysis of NSAIDs: assessment of pharmacokinetic and physicochemical properties using 3D-QSPkR approach.

European journal of medicinal chemistry 20120701

The effect of renal administration of a selective cyclooxygenase-2 inhibitor or stable prostaglandin I2 analog on the progression of sclerotic glomerulonephritis in rats.

Clinical and experimental nephrology 20120401

Spectrofluorimetric determination of etodolac, moxepril HCl and fexofenadine HCl using europium sensitized fluorescence in bulk and pharmaceutical preparations.

Journal of fluorescence 20120101

Etodolac blocks the allyl isothiocyanate-induced response in mouse sensory neurons by selective TRPA1 activation.

Pharmacology 20120101

The effects of the selective cyclooxygenase-2 inhibitor on endometrial cytological findings in uterine endometrial cancer patients.

Acta cytologica 20120101

Effects of a selective COX-2 inhibitor in patients with uterine endometrial cancers.

Archives of gynecology and obstetrics 20111201

Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).

PLoS computational biology 20111201

Comparative evaluation of efficacy and safety of etodolac and diclofenac sodium injection in patients with postoperative orthopedic pain.

Current medical research and opinion 20111101

Acute generalized exanthematous pustulosis due to etodolac in a patient with an iliopsoas muscle abscess.

Acta dermato-venereologica 20110901

Etodolac improves 5-FU sensitivity of head and neck cancer cells through inhibition of thymidylate synthase.

Anticancer research 20110901

The effect of β-adrenergic blockade and COX-2 inhibition on healing of colon, muscle, and skin in rats undergoing colonic anastomosis.

International journal of clinical pharmacology and therapeutics 20110901

In vitro and in vivo inhibitory effect of three Cox-2 inhibitors and epithelial-to-mesenchymal transition in human bladder cancer cell lines.

British journal of cancer 20110726

Randomized double-blind trial of sulindac and etodolac to eradicate aberrant crypt foci and to prevent sporadic colorectal polyps.

Clinical cancer research : an official journal of the American Association for Cancer Research 20110601

Development and in vitro/in vivo evaluation of etodolac controlled porosity osmotic pump tablets.

AAPS PharmSciTech 20110601

Improving postoperative immune status and resistance to cancer metastasis: a combined perioperative approach of immunostimulation and prevention of excessive surgical stress responses.

Annals of surgery 20110401

High specific activity tritiation of several biologically active indoles.

Applied radiation and isotopes : including data, instrumentation and methods for use in agriculture, industry and medicine 20110201

Influence of nonsteroidal anti-inflammatory drugs on the antiplatelet effects of aspirin in rats.

Biological & pharmaceutical bulletin 20110101

The enantiomers of etodolac, a racemic anti-inflammatory agent, play different roles in efficacy and gastrointestinal safety.

Biological & pharmaceutical bulletin 20110101

Effect of beta blocker combined with COX-2 inhibitor on colonic anastomosis in rats.

International journal of colorectal disease 20101201

R-etodolac induces E-cadherin and suppresses colitis-related mouse colon tumorigenesis.

Oncology reports 20101201

Polymeric surfactant based etodolac chewable tablets: formulation and in vivo evaluation.

AAPS PharmSciTech 20101201

Transcription factor NF-κB inhibitors as single therapeutic agents or in combination with classical chemotherapeutic agents for the treatment of hematologic malignancies.

Current molecular pharmacology 20101101

Synthesis and SAR studies of 1,4-benzoxazine MenB inhibitors: novel antibacterial agents against Mycobacterium tuberculosis.

Bioorganic & medicinal chemistry letters 20101101

Assessment of the efficacy of pamidronate in ankylosing spondylitis: an open prospective trial.

Singapore medical journal 20101101

Efficacy and safety of etodolac-paracetamol fixed dose combination in patients with knee osteoarthritis flare-up: a randomized, double-blind comparative evaluation.

The Clinical journal of pain 20100901

A multicentric, randomized, comparative clinical trial to evaluate the efficacy and safety of S-etodolac in the treatment of osteoarthritis in Indian patients.

International journal of clinical pharmacology and therapeutics 20100701

In vitro and ex vivo inhibition of canine cyclooxygenase isoforms by robenacoxib: a comparative study.

Research in veterinary science 20100601

Sacroiliitis and severe disability due to isotretinoin therapy.

Rheumatology international 20100501

Profiling of cell cycle genes of breast cells exposed to etodolac.

Oncology reports 20100501

Blurred vision and weakness in a 60-year-old woman.

The American journal of emergency medicine 20100501

Chemopreventive activities of etodolac and oxyphenbutazone against mouse skin carcinogenesis.

Bioorganic & medicinal chemistry letters 20100415

Preventive effects of etodolac, a selective cyclooxygenase-2 inhibitor, on cancer development in extensive metaplastic gastritis, a Helicobacter pylori-negative precancerous lesion.

International journal of cancer 20100315

Improving survival rates in two models of spontaneous postoperative metastasis in mice by combined administration of a beta-adrenergic antagonist and a cyclooxygenase-2 inhibitor.

Journal of immunology (Baltimore, Md. : 1950) 20100301

The cyclooxygenase-2 selective inhibitor, etodolac, but not aspirin reduces neovascularization in a murine ischemic hind limb model.

European journal of pharmacology 20100210

Enhanced oral bioavailability of etodolac by self-emulsifying systems: in-vitro and in-vivo evaluation.

The Journal of pharmacy and pharmacology 20100201

Crystal and molecular structure of beta-cyclodextrins functionalized with the anti-inflammatory drug Etodolac.

Biopolymers 20091201

Preparative resolution of etodolac enantiomers by preferential crystallization method.

Archives of pharmacal research 20091001

In vitro and in vivo characteristics of a thermogelling rectal delivery system of etodolac.

AAPS PharmSciTech 20090901

Racemic Etodolac is cytotoxic and cytostatic for B-cell precursor acute lymphoblastic leukemia cells.

Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie 20090801

Reversible cerebral vasoconstriction syndrome: case report.

The journal of headache and pain 20090801

Evidence-based review of clinical studies on pharmacology (non-anesthetic studies).

Journal of endodontics 20090801

Paradoxical effects of a selective cyclooxygenase-2 inhibitor, etodolac, on proliferative changes of forestomach in alloxan-induced diabetic rats.

Experimental and toxicologic pathology : official journal of the Gesellschaft fur Toxikologische Pathologie 20090701

Etodolac/cyclodextrin formulations: physicochemical characterization and in vivo pharmacological studies.

Drug development and industrial pharmacy 20090701

Inhibitory effect of nonsteroidal anti-inflammatory drugs on adenosine transport in vascular smooth muscle cells.

European journal of pharmacology 20090610

Etodolac attenuates mechanical allodynia in a mouse model of neuropathic pain.

Journal of pharmacological sciences 20090401

Cyclooxygenase (COX)-inhibiting drug reduces HSV-1 reactivation in the mouse eye model.

Current eye research 20090301

The efficacy of prostaglandin E1 derivative in patients with lumbar spinal stenosis.

Spine 20090115

Single dose oral etodolac for acute postoperative pain in adults.

The Cochrane database of systematic reviews 20090101

Dextran-etodolac conjugates: synthesis, in vitro and in vivo evaluation.

Acta poloniae pharmaceutica 20090101

COX-2 inhibition attenuates cough reflex sensitivity to inhaled capsaicin in patients with asthma.

Journal of investigational allergology & clinical immunology 20090101

The risk of acute myocardial infarction with etodolac is not increased compared to naproxen: a historical cohort analysis of a generic COX-2 selective inhibitor.

Journal of cardiovascular pharmacology and therapeutics 20081201

Improvement of the etodolac purity test by reversed phase high-performance liquid chromatography.

Die Pharmazie 20081201

The effects of etodolac, nimesulid and naproxen sodium on the frequency of sister chromatid exchange after enclused third molars surgery.

Yonsei medical journal 20081031

Comparative pharmacological study of free radical scavenger, nitric oxide synthase inhibitor, nitric oxide synthase activator and cyclooxygenase inhibitor against MPTP neurotoxicity in mice.

Metabolic brain disease 20080901

Synthesis, in vitro, and in vivo biological evaluation and molecular docking simulations of chiral alcohol and ether derivatives of the 1,5-diarylpyrrole scaffold as novel anti-inflammatory and analgesic agents.

Bioorganic & medicinal chemistry 20080901

Determination of enantiomeric impurity of etodolac by capillary electrophoresis using (2-hydroxypropyl)-beta-cyclodextrin.

Archives of pharmacal research 20080901

Chiral non-steroidal anti-inflammatory drugs--a review.

Journal of the Indian Medical Association 20080901

The role of non-steroidal anti-inflammatory drugs in the risk of development and treatment of hematologic malignancies.

Leukemia & lymphoma 20080801

In vitro inhibition of CYP1A2 by model inhibitors, anti-inflammatory analgesics and female sex steroids: predictability of in vivo interactions.

Basic & clinical pharmacology & toxicology 20080801

Towards the first inhibitors of trihydroxynaphthalene reductase from Curvularia lunata: synthesis of artificial substrate, homology modelling and initial screening.

Bioorganic & medicinal chemistry 20080601

Analysis of flurbiprofen, ketoprofen and etodolac enantiomers by pre-column derivatization RP-HPLC and application to drug-protein binding in human plasma.

Journal of pharmaceutical and biomedical analysis 20080414

Phase I study of a novel pro-apoptotic drug R-etodolac in patients with B-cell chronic lymphocytic leukemia.

Investigational new drugs 20080401

Chemopreventive effects of a selective cyclooxygenase-2 inhibitor (etodolac) on chemically induced intraductal papillary carcinoma of the pancreas in hamsters.

Carcinogenesis 20080401

Role of interleukin-1beta and tumor necrosis factor-alpha-dependent expression of cyclooxygenase-2 mRNA in thermal hyperalgesia induced by chronic inflammation in mice.

Neuroscience 20080318

Development and validation of a high performance liquid chromatography-tandem mass spectrometry for the determination of etodolac in human plasma.

Journal of chromatography. B, Analytical technologies in the biomedical and life sciences 20080215

Inhibitory effects of the cyclooxygenase-2 inhibitor, etodolac, on colitis-associated tumorigenesis in p53-deficient mice treated with dextran sulfate sodium.

Oncology reports 20080201

Etodolac, a selective cyclooxygenase-2 inhibitor, induces upregulation of E-cadherin and has antitumor effect on human bladder cancer cells in vitro and in vivo.

Urology 20080101

Spectrophotometric determination of etodolac in pure form and pharmaceutical formulations.

Chemistry Central journal 20080101

Combination therapy of S-1 with selective cyclooxygenase-2 inhibitor for liver metastasis of colorectal carcinoma.

Anticancer research 20080101

Singlet oxygen scavenging activity of non-steroidal anti-inflammatory drugs.

Redox report : communications in free radical research 20080101

Use of liposomes as membrane models to evaluate the contribution of drug-membrane interactions to antioxidant properties of etodolac.

Redox report : communications in free radical research 20080101

The effect of etodolac on experimental temporomandibular joint osteoarthritis in dogs.

Journal of cranio-maxillo-facial surgery : official publication of the European Association for Cranio-Maxillo-Facial Surgery 20071201

Inhibition of cyclooxygenase-2 suppresses lymph node metastasis via reduction of lymphangiogenesis.

Cancer research 20071101

SDX-308 and SDX-101, non-steroidal anti-inflammatory drugs, as therapeutic candidates for treating hematologic malignancies including myeloma.

Archiv der Pharmazie 20071001

In vitro and ex vivo permeation studies of etodolac from hydrophilic gels and effect of terpenes as enhancers.

Drug delivery 20071001

More than meets the eyes.

Journal of the Mississippi State Medical Association 20071001

R-etodolac (SDX-101) and the related indole-pyran analogues SDX-308 and SDX-309 potentiate the antileukemic activity of standard cytotoxic agents in primary chronic lymphocytic leukaemia cells.

Cancer chemotherapy and pharmacology 20070901

Treatment of multiple myeloma with SDX-308.

Drug news & perspectives 20070901

Pharmacological profiling of novel non-COX-inhibiting indole-pyran analogues of etodolac reveals high solid tumour activity of SDX-308 in vitro.

Investigational new drugs 20070801

Etodolac-induced pigmenting fixed drug eruption.

Clinical and experimental dermatology 20070501

R-Etodolac decreases beta-catenin levels along with survival and proliferation of hepatoma cells.

Journal of hepatology 20070501

One center's experience: the serology and drugs associated with drug-induced immune hemolytic anemia--a new paradigm.

Transfusion 20070401

Novel etodolac analog SDX-308 (CEP-18082) induces cytotoxicity in multiple myeloma cells associated with inhibition of beta-catenin/TCF pathway.

Leukemia 20070301

Safety of selective cyclooxygenase-2 inhibitors and a basic non-steroidal anti-inflammatory drug (NSAID) in Japanese patients with NSAID-induced urticaria and/or angioedema: Comparison of meloxicam, etodolac and tiaramide.

The Journal of dermatology 20070301

Evaluation of adverse effects of long-term oral administration of carprofen, etodolac, flunixin meglumine, ketoprofen, and meloxicam in dogs.

American journal of veterinary research 20070301

Keratoconjunctivitis sicca associated with administration of etodolac in dogs: 211 cases (1992-2002).

Journal of the American Veterinary Medical Association 20070215

Pharmacokinetics of etodolac in the horse following oral and intravenous administration.

Journal of veterinary pharmacology and therapeutics 20070201

Overproduction of PGE2 in peripheral blood monocytes of gastrointestinal cancer patients with mucins in their bloodstream.

Cancer letters 20070108

Etodolac, a selective cyclooxygenase-2 inhibitor, induces apoptosis by activating caspases in human malignant rhabdoid tumor cells (FRTK-1).

Oncology reports 20070101

Membranous nephropathy associated with the relatively selective cyclooxygenase-2 inhibitor, etodolac, in a patient with early rheumatoid arthritis.

Internal medicine (Tokyo, Japan) 20070101

Charge transfer complex studies between some non-steroidal anti-inflammatory drugs and pi-electron acceptors.

Spectrochimica acta. Part A, Molecular and biomolecular spectroscopy 20061201

Non-steroidal anti-inflammatory drug therapy for chronic lymphocytic leukemia.

Leukemia & lymphoma 20061201

Cytotoxic effect of R-etodolac (SDX-101) in combination with purine analogs or monoclonal antibodies on ex vivo B-cell chronic lymphocytic leukemia cells.

Leukemia & lymphoma 20061201

Effects of cyclooxygenase inhibition on the gastrointestinal tract.

Experimental and toxicologic pathology : official journal of the Gesellschaft fur Toxikologische Pathologie 20061101

Involvement of cyclooxygenase-2 in allergic nasal inflammation in rats.

International immunopharmacology 20061101

Case of the month. Chronic hepatitis.

JAAPA : official journal of the American Academy of Physician Assistants 20061101

The clinical pharmacology of cyclooxygenase-2-selective and dual inhibitors.

The Veterinary clinics of North America. Small animal practice 20060901

Chemoprevention of spontaneous development of hepatocellular carcinomas in fatty liver Shionogi mice by a cyclooxygenase-2 inhibitor.

Cancer science 20060801

Etodolac-liquid-filled dispersion into hard gelatin capsules: an approach to improve dissolution and stability of etodolac formulation.

Drug development and industrial pharmacy 20060801

High-grade slippage of the lumbar spine in a rat model of spondylolisthesis: effects of cyclooxygenase-2 inhibitor on its deformity.

Spine 20060715

In vivo and in vitro cytotoxicity of R-etodolac with dexamethasone in glucocorticoid-resistant multiple myeloma cells.

British journal of haematology 20060701

Different progression of tumor xenografts between mucin-producing and mucin-non-producing mammary adenocarcinoma-bearing mice.

Cancer research 20060615

Etodolac versus dexamethasone effect in reduction of postoperative symptoms following surgical endodontic treatment: a double-blind study.

Oral surgery, oral medicine, oral pathology, oral radiology, and endodontics 20060601

Microsphere-based protease assays and screening application for lethal factor and factor Xa.

Cytometry. Part A : the journal of the International Society for Analytical Cytology 20060501

Depressed-type early invasive colon cancer in a patient treated with cyclooxygenase-2 inhibitor.

Digestive diseases and sciences 20060501

Zaltoprofen, a non-steroidal anti-inflammatory drug, inhibits bradykinin-induced pain responses without blocking bradykinin receptors.

Neuroscience research 20060401

Use of force plate analysis to assess the analgesic effects of etodolac in horses with navicular syndrome.

American journal of veterinary research 20060401

[Intestinal side effects of COX-2 inhibitors].

Ugeskrift for laeger 20060327

Etodolac induces apoptosis and inhibits cell adhesion to bone marrow stromal cells in human myeloma cells.

Leukemia research 20060201

Etodolac, a selective cyclooxygenase-2 inhibitor, inhibits liver metastasis of colorectal cancer cells via the suppression of MMP-9 activity.

International journal of molecular medicine 20060201

Ocular adverse effects associated with cyclooxygenase-2 inhibitors.

Archives of ophthalmology (Chicago, Ill. : 1960) 20060201

[Expression of cyclooxygenase (COX)-2 in astrocytic tumors and anti-tumor effects of selective COX-2 inhibitors].

No to shinkei = Brain and nerve 20060101

Efficacy and safety of preoperative etodolac and butorphanol administration in dogs undergoing ovariohysterectomy.

Journal of the American Animal Hospital Association 20060101

[Postoperative pain management in clinics of otolaryngology].

Kulak burun bogaz ihtisas dergisi : KBB = Journal of ear, nose, and throat 20060101

Temporal relationship between use of NSAIDs, including selective COX-2 inhibitors, and cardiovascular risk.

Drug safety 20060101

Poststreptococcal reactive arthritis.

Journal of the American Podiatric Medical Association 20060101

Efficacy and safety of firocoxib in the management of canine osteoarthritis under field conditions.

Veterinary therapeutics : research in applied veterinary medicine 20060101

Combined administration of ethodolac, ascorbic acid and radiotherapy as adjuvant therapies in an extrathoracic desmoid tumor with gross postoperative residual disease; case report and review of the literature.

Journal of B.U.ON. : official journal of the Balkan Union of Oncology 20060101

Expression of receptor for advanced glycation end products during rat tongue carcinogenesis by 4-nitroquinoline 1-oxide and effect of a selective cyclooxygenase-2 inhibitor, etodolac.

Pathobiology : journal of immunopathology, molecular and cellular biology 20060101

Nonsteroidal anti-inflammatory drugs and their analogues as inhibitors of aldo-keto reductase AKR1C3: new lead compounds for the development of anticancer agents.

Bioorganic & medicinal chemistry letters 20051201

Antitumor effects of etodolac, a selective cyclooxygenase-II inhibitor, against human prostate cancer cell lines in vitro and in vivo.

Urology 20051201

Prostaglandin production during growth of Candida albicans biofilms.

Journal of medical microbiology 20051101

An overview of the recent developments in analytical methodologies for determination of COX-2 inhibitors in bulk drugs, pharmaceuticals and biological matrices.

Journal of pharmaceutical and biomedical analysis 20050915

Combination of cyclooxygenase-2 inhibitors and oxaliplatin increases the growth inhibition and death in human colon cancer cells.

Biochemical pharmacology 20050901

Etodolac inhibits EBER expression and induces Bcl-2-regulated apoptosis in Burkitt's lymphoma cells.

European journal of haematology 20050901

Inhibitory effect of etodolac, a selective cyclooxygenase-2 inhibitor, on stomach carcinogenesis in Helicobacter pylori-infected Mongolian gerbils.

Biochemical and biophysical research communications 20050826

Cyclooxygenase-2 inhibitor delays fracture healing in rats.

Acta orthopaedica 20050801

SDX-101, the R-enantiomer of etodolac, induces cytotoxicity, overcomes drug resistance, and enhances the activity of dexamethasone in multiple myeloma.

Blood 20050715

Expression of cyclooxygenase-2 in uterine endometrial cancer and anti-tumor effects of a selective COX-2 inhibitor.

International journal of oncology 20050501

In vivo effects of carprofen, deracoxib, and etodolac on prostanoid production in blood, gastric mucosa, and synovial fluid in dogs with chronic osteoarthritis.

American journal of veterinary research 20050501

Preferential and non-selective cyclooxygenase inhibitors reduce inflammation during lipopolysaccharide-induced synovitis.

Research in veterinary science 20050401

Separation of etodolac enantiomers by capillary electrophoresis. Validation and application of the chiral method to the analysis of commercial formulations.

Electrophoresis 20050301

The R-enantiomer of the nonsteroidal antiinflammatory drug etodolac binds retinoid X receptor and induces tumor-selective apoptosis.

Proceedings of the National Academy of Sciences of the United States of America 20050215

Chemopreventative effect of a cyclooxygenase-2-specific inhibitor (etodolac) on chemically induced biliary carcinogenesis in hamsters.

Carcinogenesis 20050201

Etodolac, a selective cyclo-oxygenase-2 inhibitor, enhances carboplatin-induced apoptosis of human tongue carcinoma cells by down-regulation of FAP-1 expression.

Oral oncology 20050101

Anti-inflammatory, antinociceptive, and gastric effects of Hypericum perforatum in rats.

TheScientificWorldJournal 20050101

Nonsteroidal antiinflammatory drugs: a review.

Journal of the American Animal Hospital Association 20050101

Effects of etodolac on P450 isoform-specific activities in human hepatic microsomes.

Arzneimittel-Forschung 20050101

Spectrophotometric study of etodolac complexes with copper (II) and iron (III).

Journal of AOAC International 20050101

COX-2-selective inhibitor, etodolac, suppresses choroidal neovascularization in a mice model.

Biochemical and biophysical research communications 20041210

Suppressive effects of a selective cyclooxygenase-2 inhibitor, etodolac, on 4-nitroquinoline 1-oxide-induced rat tongue carcinogenesis.

Experimental and toxicologic pathology : official journal of the Gesellschaft fur Toxikologische Pathologie 20041201

Carboxyl nonsteroidal anti-inflammatory drugs are efficiently glucuronidated by microsomes of the human gastrointestinal tract.

Biochimica et biophysica acta 20041118

Risks of clinically significant upper gastrointestinal events with etodolac and naproxen: a historical cohort analysis.

Gastroenterology 20041101

Novel cyclooxygenase-1 inhibitors discovered using affinity fingerprints.

Journal of medicinal chemistry 20040923

Warning of an adverse effect of etodolac.

Journal of the American Veterinary Medical Association 20040815

Adverse drug event reports at the United States Food And Drug Administration Center for Veterinary Medicine.

Journal of the American Veterinary Medical Association 20040815

Involvement of cell cycle regulatory proteins and MAP kinase signaling pathway in growth inhibition and cell cycle arrest by a selective cyclooxygenase 2 inhibitor, etodolac, in human hepatocellular carcinoma cell lines.

Cancer science 20040801

Pharmacokinetic difference between S-(+)- and R-(-)-etodolac in rats.

Acta pharmacologica Sinica 20040801

Effect of etodolac, a COX-2 inhibitor, on neuropathic pain in a rat model.

Brain research 20040604

Inhibition of HER-kinase activation prevents ERK-mediated degradation of PPARgamma.

Cancer cell 20040601

Effects of flunixin meglumine or etodolac treatment on mucosal recovery of equine jejunum after ischemia.

American journal of veterinary research 20040601

Determination of expression of cyclooxygenase-1 and -2 isozymes in canine tissues and their differential sensitivity to nonsteroidal anti-inflammatory drugs.

American journal of veterinary research 20040601

[A case of rheumatoid arthritis/Sjogren's syndrome with acute renal failure due to hyperuricemia associated with mizoribine therapy].

Nihon Rinsho Men'eki Gakkai kaishi = Japanese journal of clinical immunology 20040601

Inhibitory effects of etodolac, a selective COX-2 inhibitor, on the occurrence of tumors in colitis-induced tumorigenesis model in rats.

Oncology reports 20040501

Stereoselective glucuronidation and hydroxylation of etodolac by UGT1A9 and CYP2C9 in man.

Xenobiotica; the fate of foreign compounds in biological systems 20040501

MCF-7 breast cancer cell line grown in agarose culture for study of COX-2 inhibitors in three-dimensional growth system.

Cancer letters 20040308

Patient retention and hand-wrist radiograph progression of rheumatoid arthritis during a 3-year prospective study that prohibited disease modifying antirheumatic drugs.

The Journal of rheumatology 20040301

Sequence-dependent effect of a cyclooxygenase-2 inhibitor on topoisomerase I inhibitor and 5-fluorouracil-induced cytotoxicity of colon cancer cells.

Anti-cancer drugs 20040301

Efficacy of transdermal nitroglycerin combined with etodolac for the treatment of chronic post-thoracotomy pain: an open-label prospective clinical trial.

Journal of pain and symptom management 20040301

Combined treatment with selective cyclooxygenase-2 inhibitor and fluorinated pyrimidines for liver metastasis of colon cancer.

Oncology reports 20040101

Secondary hypertrophic osteoarthropathy (HOA) mimicking primary HOA (pachydermoperiostitis or Touraine-Solente-Golé) syndrome.

The Israel Medical Association journal : IMAJ 20040101

Oral etodolac, a COX-2 inhibitor, reduces postoperative pain immediately after fast-track cardiac surgery.

Journal of anesthesia 20040101

In vitro effects of selective and non-selective nonsteroidal anti-inflammatory drugs on the frequency of sister chromatid exchanges.

Drugs in R&D 20040101

Identification and prediction of promiscuous aggregating inhibitors among known drugs.

Journal of medicinal chemistry 20031009

Effects of a single arthrocentesis and a COX-2 inhibitor on disorders of temporomandibular joints. A preliminary clinical study.

The British journal of oral & maxillofacial surgery 20031001

Inhibitory effects of selective cyclooxygenase-2 inhibitors, nimesulide and etodolac, on the development of squamous cell dysplasias and carcinomas of the tongue in rats initiated with 4-nitroquinoline 1-oxide.

Cancer letters 20030925

[Combined treatment with fluorinated pyrimidines and selective cyclooxygenase-2 inhibitors for liver metastasis of colon cancer].

Nihon rinsho. Japanese journal of clinical medicine 20030901

Anti-inflammatory effect and low ulcerogenic activity of etodolac, a cyclooxygenase-2 selective non-steroidal anti-inflammatory drug, on adjuvant-induced arthritis in rats.

Pharmacology 20030601

Colon cancer cells with high invasive potential are susceptible to induction of apoptosis by a selective COX-2 inhibitor.

Cancer science 20030301

Review article: NSAIDs, gastroprotection and cyclo-oxygenase-II-selective inhibitors.

Alimentary pharmacology & therapeutics 20030201

Pain treatment with a COX-2 inhibitor after coronary artery bypass operation: a randomized trial.

The Annals of thoracic surgery 20030201

Double-blind, randomised, comparative trial of etodolac SR versus diclofenac in the treatment of osteoarthritis of the knee.

Current medical research and opinion 20030101

Superficially elevated colonic adenoma changed to undetectable configuration on ordinary endoscopy during treatment with preferential cyclooxygenase-2 inhibitor.

Journal of gastroenterology 20030101

Effect of dosing and sampling time on serum thyroxine, free thyroxine, and thyrotropin concentrations in dogs following multidose etodolac administration.

Veterinary therapeutics : research in applied veterinary medicine 20030101

A study of the comparative efficacy of three common analgesics in the control of pain after third molar surgery under local anaesthesia.

Australian dental journal 20021201

Selective cyclooxygenase-2 inhibitors show a differential ability to inhibit proliferation and induce apoptosis of colon adenocarcinoma cells.

FEBS letters 20021106

Results of thyroid function tests and concentrations of plasma proteins in dogs administered etodolac.

American journal of veterinary research 20021101

In vitro investigation of the effects of cyclooxygenase-2 inhibitors on contractile activity of the equine dorsal and ventral colon.

American journal of veterinary research 20021101

Cyclooxygenase-2 inhibitor inhibits the fracture healing.

Journal of physiological anthropology and applied human science 20020901

The effects of cyclo-oxygenase inhibitors on bile-injured and normal equine colon.

Equine veterinary journal 20020701

Sustained ER Ca2+ depletion suppresses protein synthesis and induces activation-enhanced cell death in mast cells.

The Journal of biological chemistry 20020419

Enhanced clearance of leukemic lymphocytes in B-cell chronic lymphocytic leukemia with etodolac.

Blood 20020401

Regulation of prostaglandin production in an immortalized human myometrial cell line by cytokines and non-steroidal anti-inflammatory drugs.

European journal of obstetrics, gynecology, and reproductive biology 20020110

Effects of etodolac, a selective cyclooxygenase-2 inhibitor, on the expression of E-cadherin-catenin complexes in gastrointestinal cell lines.

Journal of gastroenterology 20020101

Search of antimicrobial activity of selected non-antibiotic drugs.

Acta poloniae pharmaceutica 20020101

Cyclooxygenase-1 and cyclooxygenase-2 selectivity of non-steroidal anti-inflammatory drugs: investigation using human peripheral monocytes.

The Journal of pharmacy and pharmacology 20011201

Regioselective biomimetic oxidation of etodolac with iodosylbenzene catalyzed by halogenated and perhalogenated metalloporphyrins in dichloromethane.

Chemical & pharmaceutical bulletin 20011001

Nonsteroidal anti-inflammatory drugs for perioperative pain control.

Medicine and health, Rhode Island 20011001

Comparison of the upper gastrointestinal effects of etodolac and aspirin in healthy dogs.

The Journal of veterinary medical science 20011001

Does cyclooxygenase-2 inhibitor prevent renal tissue damage in unilateral ureteral obstruction?

The Journal of urology 20010901

Cyclooxygenase selectivity of non-steroid anti-inflammatory drugs in humans: ex vivo evaluation.

European journal of pharmacology 20010824

Long-term temporal evaluation of ground reaction forces during development of experimentally induced osteoarthritis in dogs.

American journal of veterinary research 20010801

Isolation of an unknown metabolite of the non-steroidal anti-inflammatory drug etodolac and its identification as 5-hydroxy etodolac.

Journal of pharmaceutical and biomedical analysis 20010701

Induction of apoptosis by cyclooxygenase-2 inhibitors in prostate cancer cell lines.

International journal of urology : official journal of the Japanese Urological Association 20010701

Effects of cyclooxygenase-2 inhibitor on gastric acid secretion in Helicobacter pylori-infected C57BL/6 mice.

Scandinavian journal of gastroenterology 20010601

Tumor invasiveness and liver metastasis of colon cancer cells correlated with cyclooxygenase-2 (COX-2) expression and inhibited by a COX-2-selective inhibitor, etodolac.

International journal of cancer 20010315

Direct superoxide scavenging activity of nonsteroidal anti-inflammatory drugs: determination by electron spin resonance using the spin trap method.

Headache 20010201

[Suppressive efffects of clarithromycin and cyclooxygenase-2 inhibitor, etodolac on N-nitrosobis(2-hydroxypropyl)amine(BHP)- induced experimental lung neoplasm in rats].

The Japanese journal of antibiotics 20010201

Nimesulide, a balanced drug for the treatment of osteoarthritis.

Clinical and experimental rheumatology 20010101

The role of eicosanoids in the process of adaptation following massive bowel resection in the rat.

JPEN. Journal of parenteral and enteral nutrition 20010101

The effect of etodolac on bile salt and histamine-mediated gastric mucosal injury in the rat.

Journal of physiology, Paris 20010101

Effects of some pharmacological agents on the survival of unipedicled venous flaps: an experimental study.

Microsurgery 20010101

Sulindac and a cyclooxygenase-2 inhibitor, etodolac, increase APC mRNA in the colon of rats treated with azoxymethane.

Gut 20001201

Immune hemolytic anemia caused by sensitivity to a metabolite of etodolac, a nonsteroidal anti-inflammatory drug.

Transfusion 20000601

The effect of NSAIDs and a COX-2 specific inhibitor on Helicobacter pylori-induced PGE2 and HGF in human gastric fibroblasts.

Alimentary pharmacology & therapeutics 20000401

Reactive oxygen species are involved in the apoptosis induced by nonsteroidal anti-inflammatory drugs in cultured gastric cells.

European journal of pharmacology 19991103

Biochemical and pharmacological profile of a tetrasubstituted furanone as a highly selective COX-2 inhibitor.

British journal of pharmacology 19970501

Nonsteroidal antiinflammatory drug induced hypersensitivity vasculitis clinically mimicking temporal arteritis.

The Journal of rheumatology 19960101

Fulminant hepatic failure associated with etodolac use.

The American journal of gastroenterology 19950401

Anti-inflammatory effects of etodolac: comparison with other non-steroidal anti-inflammatory drugs.

Biological & pharmaceutical bulletin 19941201

Efficacy and tolerability of etodolac in aged patients affected by degenerative joint disease (osteoarthritis) in its active phase.

International journal of clinical pharmacology research 19940101

[Allergic vasculitis caused by etodolac. The first case].

Annales de medecine interne 19890101

Comparative effects of etodolac, indomethacin, and benoxaprofen on icosanoid biosynthesis.

Inflammation 19841201